PMC6884981_01
An 85-year-old male with history of prostate cancer status post radiation treatment presented with rising prostate- specific antigen level of 6.1 ng/mL. (a) Axumin positron emission tomography-computed tomography axial image showing increased radiotracer uptake (standardized uptake value maximum of 5.3) in the left internal iliac lymph node (yellow arrow). (b) Magnetic resonance imaging pelvis T1 weighted axial image depicting a few enlarged bilateral internal iliac lymph nodes (red arrow) which were otherwise inconclusive for recurrence.
JCIS-9-49-g001.jpg
PMC6884981_01_JCIS-9-49-g001.jpg
F1
Subsequently, Axumin PET showed abnormal radiotracer uptake with a standardized uptake value maximum (SUVmax) of 5.3 only in the enlarged left internal iliac lymph node, consistent with metastatic lymphadenopathy [Figure 1].
A 76-year-old male with history of prostate cancer status post brachytherapy with rising prostate-specific antigen level of 6.4 ng/mL. (a) Axumin positron emission tomography-computed tomography (CT) axial image showing focal asymmetric tracer activity in the prostate with standardized uptake value maximum (SUVmax) 2.1 (yellow arrow) in contrast to marrow activity (SUVmax 1.4). (b) Non-contrast CT of pelvis for radiation planning axial image showing brachytherapy seeds but no visible mass (red arrow).
JCIS-9-49-g002.jpg
PMC6884981_01_JCIS-9-49-g002.jpg
F2
Axumin PET revealed focal asymmetric tracer activity with SUVmax 2.1 in the central prostate, slightly right to the midline [Figure 2].
An 88-year-old male with history of prostate cancer status post prostatectomy presented with progressive back pain and prostate- specific antigen level of 6.9 ng/mL concerning for recurrence. (a) Bone scan was negative. (b) Axumin positron emission tomography- computed tomography axial image demonstrating intense tracer uptake (standardized uptake value maximum 6.4) in the left posterolateral aspect of the T8 vertebral body (red arrow). (c) Pre-biopsy magnetic resonance imaging performed showing T2 hypointense lesion (yellow arrow) measuring 2.2 cm which was consistent with osteoblastic metastasis on biopsy.
JCIS-9-49-g003.jpg
PMC6884981_01_JCIS-9-49-g003.jpg
F3
However, a focus of intense tracer uptake (SUVmax 6.4) was noted in a 2.2 cm sclerotic lesion in the posterolateral aspect of the T8 vertebral body, consistent with osteoblastic metastasis [Figure 3].